Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefotiam hydrochloride, and adenosine monophosphate for injection; voglibose tablets, ansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; and raw materials, intermediates, and other products. Its products are used in cardiovascular and cerebrovascular, diuretic, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, and other treatment areas. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is headquartered in Nanjing, China.
Metrics to compare | 300584 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300584PeersSector | |
---|---|---|---|---|
P/E Ratio | 122.9x | 46.9x | −0.5x | |
PEG Ratio | 10.37 | −1.40 | 0.00 | |
Price/Book | 5.0x | 3.1x | 2.6x | |
Price / LTM Sales | 9.5x | 5.1x | 3.3x | |
Upside (Analyst Target) | - | 2.7% | 42.8% | |
Fair Value Upside | Unlock | −6.5% | 6.5% | Unlock |